Immunotherapy and Antivascular Targeted Therapy in Patients’ Treatment with Concurrent Malignant Tumors after Organ Transplantation: Opportunity or Challenge

Table 2

Antivascular targeting therapy in patients with combined malignancy after organ transplantation.

Date	Author	Age	Gender	Protopathy	Allograft	Time from transplant to cancer	Tumor type	ISD	OR	Antitumor scheme	Tumor remission
2015	Fatma Yalcin Müsri et al. [14]	45,; 54	Male	Renal failure	Kidney	120,228 months	Colorectal cancer	EVE+TAC	NO		PD
2017	Wu et al. [15]	61	Female	End-stage renal disease	Kidney	60 months	Relapse ureter UC	Prednisone+TAC+MMF	NO		PD
2018	Yu et al. [16]	36	Male	HCC	Liver	6.5 months	Lung metastases	TAC+Sir	NO		PR
2020	Zhuang et al. [17]	54	Male	HCC	Liver	3 months	Lung metastases	Low-dose TAC (trough level, 4-6 ng/mL)	NO	Regorafenib, anlotinib, apatinib, lenvatinib	SD
2020	Zhang et al. [18]	56	Male	HCC	Liver	3 months	Leiomyosarcoma		NO	Apatinib	PD
2020	Onodera et al. [19]	67	Male	Chronic renal failure	Kidney	132 months	Colorectal cancer	TAC+MMF	NO	cycles, then cycles, respectively, after 6 cycles, discontinued BEV	NA
2021	Kasherman et al. [20]	44	Female	IgA nephropathy	Kidney	36 months	HGSOC	TAC	NO	Paclitaxel with BEV	PR
2021	Khaled et al. [21]	35	Male	Fibrolamellar HCC	Liver	48 months	HCC		NO	months	PR
2021	Zhang et al. [22]	43	Male	NA	Kidney	9 months	Synovial sarcoma	NA	NO	Anlotinib	CR
2021	Zhang et al. [22]	33	Male	NA	Kidney	13 months	Synovial sarcoma	NA	NO	Anlotinib	CR

Aza: azathioprine; HGSOC: high-grade serous ovarian carcinoma; CRC: colorectal cancer; LT: liver transplant; CSA: cyclosporin A; PFS: progression-free; EVE: everolimus; UC: urothelium carcinoma; ISD: immunosuppressive drugs; MMF: mycophenolate mofetil; TAC: tacrolimus; Sir: sirolimus; BEV: bevacizumab; CR: complete response; PR: partial response; SD: stable disease; PD: progressive disease; NA: not available. The DCR is the percentage of patients whose tumors shrank or stabilized and remained for a certain period of time and includes cases in CR, PR, and SD.